Pasithea Therapeutics reported net income of -$5.29M for the quarter ended Jun 2026. This income statement covers 23 quarters of results from Dec 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.45M | 0.52M | 1.15M | 1.33M | 1.33M | 1.30M | 1.31M | 1.31M | 1.04M | 1.04M | 1.04M | 1.04M | 1.04M | 1.10M | 2.21M | 5.64M | 7.44M | 7.03M | 24.94M | 33.41M | |||
| Revenue & cost | |||||||||||||||||||||||
| Revenue | 0.01M | 0.01M | 0.22M | 0.24M | |||||||||||||||||||
| Gross Profit | 721.00 | -0.00M | 0.13M | 0.24M | |||||||||||||||||||
| Operating items | |||||||||||||||||||||||
| Research & DevelopmentR&D | 1.16M | 1.39M | 1.10M | 2.03M | 1.62M | 3.35M | 1.75M | 2.36M | 1.58M | 1.51M | 1.73M | 2.15M | 1.36M | 2.74M | 2.94M | 3.69M | |||||||
| Selling, General & AdministrativeSG&A | 1.27M | 1.95M | 2.41M | 3.08M | 3.22M | 3.94M | 2.12M | 1.80M | 2.16M | 1.80M | 2.29M | 1.59M | 1.42M | 1.75M | 1.95M | 1.66M | 1.75M | 7.51M | 1.93M | 2.03M | |||
| Restructuring CostsRestructuring | 0.33M | 655.00 | 45.00 | ||||||||||||||||||||
| Operating ExpensesOpex | 1.27M | 1.95M | 2.73M | 3.08M | 4.38M | 5.32M | 3.21M | 3.83M | 3.79M | 5.15M | 4.04M | 3.95M | 3.00M | 3.26M | 3.68M | 3.81M | 3.11M | 10.26M | 4.88M | 5.71M | |||
| Operating IncomeOp. Inc | -1.27M | -1.96M | -2.40M | -3.08M | -4.25M | -5.08M | -3.21M | -3.83M | -3.79M | -5.15M | -4.04M | -3.95M | -3.00M | -3.26M | -3.68M | -3.81M | -3.11M | -10.26M | -4.88M | -5.71M | |||
| EBIT | -1.27M | -1.96M | -2.40M | -3.08M | -4.25M | -5.08M | -3.21M | -3.83M | -3.79M | -5.15M | -4.04M | -3.95M | -3.00M | -3.26M | -3.68M | -3.81M | -3.11M | -10.26M | -4.88M | -5.71M | |||
| Non-operating items | |||||||||||||||||||||||
| Non Operating Interest Expenses | 0.01M | -0.12M | |||||||||||||||||||||
| Non Operating Investment Income | -0.01M | ||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.13M | 0.17M | 0.15M | 0.11M | 0.08M | 0.08M | 0.05M | 0.05M | 0.04M | 0.18M | 0.45M | 0.41M | |||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.04M | -277.00 | -0.01M | 0.12M | 0.15M | 0.11M | 0.01M | 0.03M | -0.03M | 0.35M | 0.02M | 0.04M | |||||||||||
| Non Operating IncomeNon Op. Inc. | -0.25M | 2.59M | 0.83M | 0.42M | -0.34M | -0.05M | 0.23M | 0.18M | 0.12M | 0.18M | 0.08M | 0.00M | 0.08M | 0.12M | 0.09M | 0.07M | 0.15M | 2.01M | 0.44M | ||||
| Net income details | |||||||||||||||||||||||
| EBT | -1.53M | 0.63M | -1.57M | -2.66M | -4.59M | -5.12M | -3.27M | -3.60M | -3.61M | -5.03M | -3.86M | -3.87M | -3.00M | -3.18M | -3.56M | -3.72M | -3.04M | -10.11M | -2.87M | -5.27M | |||
| Profit After TaxPAT | -1.53M | 0.62M | -1.57M | -2.66M | -4.67M | -4.98M | -3.54M | -3.76M | -3.62M | -5.05M | -3.86M | -3.87M | -3.03M | -3.15M | -3.56M | -3.72M | -3.04M | -10.11M | -2.87M | -5.29M | |||
| Income from Continuing OperationsIncome (Continuing) | -1.53M | 0.63M | -1.57M | -2.66M | -4.59M | -5.12M | -3.27M | -3.60M | -3.61M | -5.03M | -3.86M | -3.87M | -3.00M | -3.18M | -3.56M | -3.72M | -3.04M | -10.11M | -2.87M | -5.27M | |||
| Income from Discontinued OperationsIncome (Discontinued) | -0.33M | -0.47M | 0.40M | -3.42M | -0.27M | -0.17M | -0.08M | ||||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -1.53M | 0.63M | -1.90M | -3.13M | -4.19M | -8.53M | -3.54M | -3.76M | -3.61M | -5.11M | -3.86M | -3.87M | -3.00M | -3.18M | -3.56M | -3.72M | -3.04M | -10.11M | -2.87M | -5.27M | |||
| Income towards Parent CompanyParent Net Inc | -1.53M | 0.63M | -1.90M | -3.13M | -4.19M | -8.53M | -3.54M | -3.76M | -3.61M | -5.11M | -3.86M | -3.87M | -3.00M | -3.18M | -3.56M | -3.72M | -3.04M | -10.11M | -2.87M | -5.27M | |||
| Net Income towards Common StockholdersNet Income | -1.53M | 0.63M | -1.90M | -3.13M | -4.19M | -8.53M | -3.54M | -3.76M | -3.61M | -5.11M | -3.86M | -3.87M | -3.00M | -3.18M | -3.56M | -3.72M | -3.04M | -10.11M | -2.87M | -5.27M | |||
| Additional items | |||||||||||||||||||||||
| EPS (Basic) | -3.41 | 1.21 | -1.65 | -2.67 | -3.16 | -6.76 | -2.71 | -2.88 | -2.87 | -4.17 | -3.70 | -3.71 | -2.87 | -2.90 | -1.61 | -0.66 | -0.41 | -1.44 | -0.12 | -0.16 | |||
| EPS (Diluted) | -3.41 | 1.21 | -1.65 | -2.67 | -3.16 | -6.76 | -2.71 | -2.88 | -2.87 | -4.17 | -3.70 | -3.71 | -2.87 | -2.90 | -1.61 | -0.66 | -0.41 | -1.44 | -0.12 | -0.16 | |||
| Shares Outstanding | 0.45M | 0.52M | 1.15M | 1.17M | 1.33M | 1.26M | 1.30M | 1.31M | 1.26M | 1.23M | 1.04M | 1.04M | 1.04M | 1.10M | 2.21M | 5.64M | 7.44M | 7.03M | 24.34M | 32.10M | |||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.45M | 0.52M | 1.15M | 1.17M | 1.33M | 1.26M | 1.30M | 1.31M | 1.26M | 1.23M | 1.04M | 1.04M | 1.04M | 1.10M | 2.21M | 5.64M | 7.44M | 7.03M | 24.34M | 32.10M | |||
| EBITDA | -1.27M | -1.96M | -2.40M | -3.08M | -4.25M | -5.08M | -3.21M | -3.83M | -3.79M | -5.15M | -4.04M | -3.95M | -3.00M | -3.26M | -3.68M | -3.81M | -3.11M | -10.26M | -4.88M | -5.71M | |||
| Interest ExpensesInt Expense | 0.01M | -0.12M |